Theravance Biopharma
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Theravance Biopharma sits in the top decile of US sponsors by registered trial count (#448 of 15,742 sponsors by registered trial count).
Theravance Biopharma: 38 sponsored US clinical trials, none currently recruiting.
Theravance Biopharma sponsors 38 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 31 completed. 5 of these trials are in Phase 3-4 (later-stage) and 32 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy Adults, Elderly Subjects, with 2 trials.
Top-decile sponsor footprint
Theravance Biopharma ranks in the top decile of sponsors by registered trial count (#448 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
31 of 37 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
38 total, page 1 of 1
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy
NCT05696717
Phase 4 COPD and Suboptimal Inspiratory Flow Rate
NCT05165485
TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental Oxygenation
NCT05091723
Comparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID-19
NCT04681079
Thorough QT Study to Evaluate Ampreloxetine in Healthy Subjects
NCT04688632
Single Dose Bioavailability and Ethnobridging PK Study in Healthy Subjects
NCT04587713
TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study
NCT03920254
TD-0903 for ALI Associated With COVID-19
NCT04402866
Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855
NCT04200573
Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
NCT04095793
Single and Multiple Ascending Dose, First-in- Human Study in Healthy Subjects
NCT04044339
Efficacy & Safety of TD-1473 in Ulcerative Colitis
NCT03758443
Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
NCT03829657
Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
NCT03750552
Multiple Dose Ethnobridging PK Study in Healthy Subjects
NCT03750565
Efficacy and Safety of TD-1473 in Crohn's Disease
NCT03635112
Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study
NCT03555617
Drug-Drug Interaction (DDI) Study for TD-9855
NCT03432793
TD-1473 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects
NCT03408470
TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)
NCT02705755
TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC)
NCT03103412
Multiple Ascending Dose Study of TD-1439 in Healthy Adult and Elderly Subjects
NCT02954263
TD-1473 for Active Ulcerative Colitis (UC)
NCT02818686
Single Ascending Dose Study of TD-1439 in Healthy Subjects
NCT02903095
Multiple Ascending Dose Study of TD-0714 in Healthy and Elderly Subjects
NCT02709928
SAD and MAD Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of TD-1473 in Healthy Subjects
NCT02657122
Single Ascending Dose Study of TD-0714 in Healthy Subjects
NCT02639078
TD-6450 MAD Study in HCV Infected Subjects
NCT02116543
TD-6450 SAD and MAD in Healthy Subjects
NCT02022306
TD-9855 Mass Balance Study
NCT01924143
TD-1607 MAD Study in Healthy Subjects
NCT01949103
TD-1607 SAD Study in Healthy Subjects
NCT01791049
Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis
NCT01718938
Phase 2 Study of TD-9855 to Treat Fibromyalgia
NCT01693692
A Phase 1, Multiple Intravenous Dose Study to Examine Safety, Tolerability, and PK of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy Subjects
NCT01644240
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT01458340
A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC)
NCT01401985
TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection
NCT00442832
How the Theravance Biopharma early-phase archive is shaped
38 indexed studies, none listed as recruiting (0% open); 31 completed (82%).
Phase mix: 5 late (III/IV) vs 32 early (I/II) (early-phase heavy).
Top condition: Healthy Adults, Elderly Subjects (2 trials), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Theravance Biopharma: archived-pipeline peers nationwide
Peers matched on 38 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Theravance Biopharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 38 archived trials
- Acerta Pharma · 38 trials · 0% recruiting
- Astex Pharmaceuticals · 38 trials · 0% recruiting
- Corewell Health West · 38 trials · 11% recruiting
- DePuy Orthopaedics · 38 trials · 5% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Theravance Biopharma page
38 registered trials is a research-attention snapshot, not an endorsement of Theravance Biopharma or any single study.
- None of Theravance Biopharma's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Healthy Adults, Elderly Subjects is the condition Theravance Biopharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy Adults, Elderly Subjects trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Theravance Biopharma pipeline card: 38 registered trials from official public datasets.Report a data error.